Antiphospholipid syndrome medical therapy

Jump to navigation Jump to search

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome medical therapy

CDC on Antiphospholipid syndrome medical therapy

Antiphospholipid syndrome medical therapy in the news

Blogs on Antiphospholipid syndrome medical therapy

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

The most important therapy for symptomatic antiphospholipid syndrome is platelet inhibition with or without anticoagulation. Platelet inhibition is often achieved with aspirin, while warfarin and heparin are the mainstays of anticoagulation. Typically, there is no indication for primary prophylaxis. Immunosuppression, the use of intravenous immunoglobulin, and plasmapheresis have also been used with modest success.

Medical Therapy

General principles and choice of anticoagulation

The mainstay of treatment in antiphospholipid syndrome(APS) is anticoagulation. The choice of anticoagulant is heparin, which is given in overlap with warfarin. In cases where warfarin is contraindicated such as pregnancy, low molecular weight heparin (LMWH) is used.

Treatment of acute thromosis in APS

  • The choice of treatment for acute thrombosis in APS is low molecular weight heparin (LMWH).
  • It is overlapped with warfarin for a minimum of 4-5 days.
  • It is continued as long as the International normalized ratio (INR) is in the therapeutic range that is 2-3.

Treatment of recurrent thrombosis despite anticoagulation

Management of noncriteria manifestations

Limited role of alternative therapies

Anticoagulation in pregnancy

  • During pregnancy, low molecular weight heparin and low-dose aspirin are used to avoid warfarin's teratogenicity.
  • The therapy is initiated at the beginning of pregnancy and continued until the time of delivery.
  • Women with recurrent miscarriage are often advised to take low dose aspirin and to start low molecular weight heparin treatment after missing a menstrual cycle.
  • For women with previous history of clots, higher dose of low molecular weight heparin is used.

Treatment of refractory cases in pregnancy

  • Intravenous immunoglobulin(IgG) and corticosteroids are used for patients with refractory cases in pregnancy.

Immunomodulatory agents

Treatment of catastrophic disease

Optimal treatment has not been clearly defined in this condition. We are limited to data from small case report studies. These patients often display a fulminant course with rapid multiorgan system failure, so multiple interventions are often desperately tried in hopes that the patient might respond to something and survive.

References

Template:WH Template:WS